INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Volume 10, Number 6 • June 1989

Special Update:
Hospital Epidemiology:
New Challenges and Controversies

Sponsored by
Infection Control and Hospital Epidemiology and
The Society of Hospital Epidemiologists of America

The Official Journal of The Society of Hospital Epidemiologists of America

https://doi.org/10.1017/S0899823X00080946 Published online by Cambridge University Press

Tme spent in die O.R. shouldn't be hazardous duty.

https://doi.org/10.1017/S0899823X00080946 Published online by Cambridge University Press



Your staff is exposed to infectious fluids and waste every day. It's part of the job.

That's why Baxter Operating Room Division offers a complete line of products and services designed to protect both staff and patient.

3

Products like our Medi-Vac® suction canister system. Our -Jackson-Pratt@ closed wound drainage system, and Pour-Safe'" exudate disposal bags. All are designed for safe collection, retention and disposal of infectious waste.

In addition, Convertors@ poly-reinforced impervious gowns, and drapes with fluid collection pouches help protect staff and patient during fluid-intense procedures. Iso•Bac® absorbent reinforcement in our drapes prevents strike-through and reduces pathogenic growth.

For staff safety and reduction of disposal costs, we also supply training videos and seminars on segregation and minimization of infectious waste.

What we're doing to make the O.R. safe is considerable. But then, consider that the Operating Room Division is made up of three of the most well-known names in the business: Convertors/Custom Sterile, Pharmaseal® Surgical and V. Mueller.@ Together, we're uniquely qualified to help you with any clinical or business issues you face.

To find out more about how we're taking the hazard out of hazardous duty, contact your local Baxter Operating Room Division sales representative, or write Baxter Healthcare Corporation, Operating Room Division, 1500 Waukegan Rd., McGaw Park, IL 60085.

Operating Room Division

Baxter

https://doi.org/10.1017/S0899823X00080946 Published online by Cambridge University Press

EDITORIAL OFFICES
Vanderbilt University School of Medicine
A-1131 Medical Center North
Nashville, TN 37232-2637
(615) 343-1095; (615) 343-1882 (FAX)
Email: iche@mcmail.vanderbilt.edu

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY®

SLACK Incorporated
6900 Grove Road
Thorofare, New Jersey 08086
(609) 848-1000

Vice President/Group Publisher
Richard N. Roash

Publisher
John C. Carter

Editorial Director
Jennifer Kilpatrick

Production Editor
Shirley P. Strunk, ELS

Assistant Editor
Eileen C. Anderer

Circulation Manager
Lester J. Robeson, CCCP

Production Director
Christine Malin

Production Coordinator
Joanne Patterson

Publishing Director/ Advertising
Wayne McCourt

Pharmaceutical Group Sales Director
Michael LoPresti

Advertising Sales Representative
Jennine Kane

Classified/Recruitment Sales Manager
Michele Burch



(ciprofloxacin HCl/Miles)

A REVOLUTIONARY ORAL ANTIMICROBIAL WITH THE POWER OF **PARENTERALS**

- Highly active ***in vitro*** against a broad range of gram-positive and gram-negative pathogens, including **methicillin-resistant *Staphylococcus aureus*** and ***Pseudomonas aeruginosa****
- For treatment of infections in the:
  - -lower respiratory **tract**† – urinary **tract**†
  - -skin/skin structure? -bones and joints?
- Convenient ***B.I.D.*** dosage-250 mg, 500 mg and 750 mg tablets

**In vitro* activity does not necessarily imply a correlation with *in vivo* results.
†**Due to susceptible strains of indicated pathogens. See indicated organisms in Brief Summary.**

CIPRO" SHOULD NOT BE USED IN CHILDREN, ADOLESCENTS, OR PREGNANT WOMEN.

A historyof hypersensitivity to ciprofloxacin is a contraindication to its use. A history of hypersensitivity to other quinolones may also contraindicate the use of ciprofloxacin.

MILES

Miles Inc.
Pharmaceutical Division
400 Morgan Lane
West Haven, CT 06516

Please see adjacent page of this advertisement for Brief Summary of Prescribing Information.

https://doi.org/10.1017/S0899823X00080946 Published online by Cambridge University Press

VOLUME 10, NUMBER 6 JUNE 1989

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

The ideas and opinions expressed by contributing authors do not necessarily reflect those of the editors or publisher.

Publisher: Infection Control and Hospital Epidemiology (ISSN-0899-823X) is published monthly by SLACK Incorporated, 6900 Grove Road, Thorofare, New Jersey 08086. Telephone: (609) 848-1000.

Subscriptions: Requests should be addressed to the publisher (except Japan). In Japan, contact Woodbell Incorporated, 4-22-11 Kitakasai, Edogawaku, Tokyo 134, Japan. Subscription rates in the US and possessions: Individual: One year - $50.00; Two years - $85.00; Three years - $115.00. Institutional: One year - $60.00; Two years - $100.00; Three years - $140.00. Canada: $15.00 additional each year; all other countries: $25.00 additional each year. Single copies of current issues may be obtained for $7.00. United States and possessions: $13.00 all other countries.

Reprints: All requests to reprint or use material published herein should be addressed to Susan S. Budd, SLACK Incorporated, 6900 Grove Road, Thorofare, NJ 08086. For reprint orders and prices, contact Joanne Patterson at (609) 848-1000.

Change of address: Notice should be sent to the publisher six weeks in advance of effective date. Include old and new addresses with zip codes. The publisher cannot accept responsibility for undelivered copies. Second-class postage is paid at Thorofare, New Jersey 08086, and additional entry points. **Postmaster:** Send address changes to SLACK Incorporated, 6900 Grove Road, Thorofare, NJ 08086.

As of Volume 1, Number 1, INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY is listed in *Index Medicus*, *Current Contents/Clinical Practice*, *Hospital Literature Index*, and *Cumulative Index to Nursing and Allied Health Literature*.